Typhoid Fever

AVANT is developing an oral vaccine (designated Ty800) to offer rapid, single-dose protection against Salmonella typhi, the cause of typhoid fever. The development of a safe and effective typhoid fever vaccine is important for protecting residents, travelers and military personnel from typhoid fever in endemic areas.

The National Institute of Allergy and Infectious Diseases (NIAID) and AVANT have entered an agreement for the NIAID to conduct a Phase 1/2 in-patient dose ranging clinical trial aimed at demonstrating the safety and immunogenicity of the Ty800 typhoid fever vaccine, which would confirm the safety and immunogenicity of the Ty800 oral vaccine observed in an earlier physician-sponsored Ty800 vaccine study.

The NIAID trial, which began in February 2006 at the Cincinnati Children's Hospital Medical Center, is an in-patient dose-escalating clinical trial which will evaluate three escalating dose levels of the vaccine in approximately 54 healthy adult volunteers, who will be followed for six months post-vaccination.